![Thomas Guiel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 9 306 $ au 31/07/2026
Thomas G.
Guiel worked as Principal at Invitrogen Corp., Vice President-Operations at CapForce, Inc., Chief Operating Officer & Executive Vice President at OncoPlex Diagnostics, Inc. from 2013 to 2018, and Chief Operating Officer at Oxford BioDynamics Plc.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OXFORD BIODYNAMICS PLC 0,15 % | 10/11/2025 | 6 288 146 ( 0,15 % ) | 9 306 $ | 31/07/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
OncoPlex Diagnostics, Inc.
 OncoPlex Diagnostics, Inc. Medical/Nursing ServicesHealth Services Operates a cancer diagnostics laboratory | Directeur des opérations | 01/01/2018 |
| OXFORD BIODYNAMICS PLC | Directeur des opérations | - |
| CAPFORCE INC. | Directeur des opérations | - |
Invitrogen Corp.
 Invitrogen Corp. Electronic Equipment/InstrumentsElectronic Technology Develops, manufactures and sells life science research kits and provides research services | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 4 |
|---|---|
Invitrogen Corp.
Invitrogen Corp. Electronic Equipment/InstrumentsElectronic Technology Develops, manufactures and sells life science research kits and provides research services | Electronic Technology |
OpGen, Inc.
 OpGen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops technologies against life-threatening, antibiotic-resistant infections using molecular diagnostics and bioinformatics | Commercial Services |
OncoPlex Diagnostics, Inc.
OncoPlex Diagnostics, Inc. Medical/Nursing ServicesHealth Services Operates a cancer diagnostics laboratory | Health Services |
Oxford BioDynamics Plc
 Oxford BioDynamics Plc BiotechnologyHealth Technology Discovers and develops novel biomarkers | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
